Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (61-70 of 145) with videos related to

Pageof 15
Sort By:
Cancer Research|May 22, 2009
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3Charlie Gourley, Adam J W Paige, Karen J Taylor, et al.
Gynecologic Oncology|May 28, 2025
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinomaYasushi Iida, Michael Churchman, Robert L Hollis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomasCharlie Gourley, John Farley, Diane M Provencher, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
The New England Journal of Medicine|March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
NPJ Precision Oncology|June 3, 2021
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratificationRobert L Hollis, Barbara Stanley, John P Thomson, et al.
Nucleic Acids Research|June 30, 2016
Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell lineJaine K Blayney, Timothy Davison, Nuala McCabe, et al.
Journal of Immunological Methods|February 25, 2012
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft modelsTerry A Gray, Nicola J MacLaine, Caroline O Michie, et al.
Cancer Research|May 17, 2011
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancerEuan A Stronach, Albandri Alfraidi, Nona Rama, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2025
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancerJoanna M Porter, Cici Jin, Michael Churchman, et al.
Pageof 15

Showing results (61-70 of 145) with videos related to

Sort By:
Pageof 15
Cancer Research|May 22, 2009
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3Charlie Gourley, Adam J W Paige, Karen J Taylor, et al.
Gynecologic Oncology|May 28, 2025
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinomaYasushi Iida, Michael Churchman, Robert L Hollis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomasCharlie Gourley, John Farley, Diane M Provencher, et al.
BMJ Open|January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancerUma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
The New England Journal of Medicine|March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
NPJ Precision Oncology|June 3, 2021
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratificationRobert L Hollis, Barbara Stanley, John P Thomson, et al.
Nucleic Acids Research|June 30, 2016
Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell lineJaine K Blayney, Timothy Davison, Nuala McCabe, et al.
Journal of Immunological Methods|February 25, 2012
Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft modelsTerry A Gray, Nicola J MacLaine, Caroline O Michie, et al.
Cancer Research|May 17, 2011
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancerEuan A Stronach, Albandri Alfraidi, Nona Rama, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2025
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancerJoanna M Porter, Cici Jin, Michael Churchman, et al.
Pageof 15